Humacyte, Inc. (HUMA) Reports Q1 Loss, Misses Revenue Estimates
Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of +10.00% and -59.76%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?